Clinical observation was made on 6 cases with Acromioclavicular separation who were treated conservatively at the Department of Orthopaedic Surgery, Pusan National University Hospital. 1) The authors experienced good functional results in those cases with conservative treatment. 2) Closed method is desirable for grade I & II acromioclavicular separation as primary treatment and also, even for grade III depending upon the situation. 3) The authors recommended the convenient Kenny-Howard sling halter as a conservative treatment in Koreans who refuse operation.
Busan ; Methods

Many unsolved probIems still remain in these in management of trochanteric fracture of hip, especially unstable type of trochanteric fracture. Among many cases of the trochanteric fracture treated during period from Jan. 1963 to July, 1973 at Busan National University Hospital, six patient has severe sequelae such as coxa vara deformity, shortening of the affected limb and ankylosis of the hip joint, which were analyzed clinically and results obtained were as follow. 1. It is the most important factor that the medial and the posterior cortex is good alignment in reduction with internal fixation and maintainance of unstable trochanteric fracture. 2. It is dangerous for the unstable type of trochanteric fracture to be reducted and maintained with only screws or plates. Jewett nail is more effective than the S-P nail and Thornton plate in internal fixation of unstable type of trochanteric franture. 3. The posterior fragments can hardly be found in A-P view but easily in lateral view 4. In cases that had not good alignments between posterior fragments the distaI fragment displaced medially and migration of the naiI, distraction of the pIate, malunion have developed in spite of prolonged immobilization in cast. 5. In one case that the severe coxa vara deformity have been developed. we performed the transverse osteotomy & fixed with Blount-V-blade plate like device. The result was good but the shortening of the limb could not prevent.
Ankylosis ; Busan ; Congenital Abnormalities ; Coxa Vara ; Extremities ; Femur ; Hip Joint ; Hip ; Humans ; Immobilization ; Osteotomy

We have studied the angiograms before and after arteriorrhaphy, which were performed on 20 cases at Busan National University Hospital. Among the cases, 15 were on upper extremity and 5 on lower extremity. The results obtained were as follows; 1. 8 cases among 19 on which angiogram were checked after arteriorrhaphy revealed the obstructive findings distal to injured vessels. 2. Necrosis did not occur following arteriorrhaphy for brachial artery, radial artery and ulnar artery and ulnar artery ruptures. On a cases of anterior tibial artery rupture, an A-K amputation was done due to progressive tissue necrosis. 3. Collateral circulations were very important pathway after brachial artery rupture and increased collateral circulations were showed on angiograms. 4. Localized thrombosis and hypertrophic vascular changes were found in 3 cases of re-exploration because of the obstruction after initial surgery.
Amputation ; Brachial Artery ; Busan ; Clinical Study ; Collateral Circulation ; Extremities ; Lower Extremity ; Necrosis ; Radial Artery ; Rupture ; Thrombosis ; Tibial Arteries ; Ulnar Artery ; Upper Extremity ; Vascular System Injuries

BACKGROUND/AIMS: Limited data are available regarding the efficacy of rivaroxaban for the treatment of cancer-associated venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety of rivaroxaban for the treatment of VTE in active cancer patients. METHODS: In this prospective, multicenter, open-label trial (NCT01989845), we enrolled patients with active cancer and objectively diagnosed lower-extremity deep vein thrombosis, pulmonary embolism (PE), or both from November 2013 to June 2016. Active cancer was defined as a histologically confirmed malignancy, which was diagnosed or treated within the previous 6 months, or as a recurrent/metastatic cancer. Patients received oral rivaroxaban 15 mg twice daily for first 3 weeks, followed by 20 mg once daily for 6 months. The primary outcome was the symptomatic recurrent VTE and the secondary outcomes included any recurrent VTE, major or clinically relevant non-major (CRNM) bleeding events, and overall mortality. All study outcomes were validated by blinded central adjudication. RESULTS: Of 124 patients enrolled, 110 (88.7%) had solid cancer, 93 (75.0%) had metastatic disease, and 110 (88.7%) were receiving chemotherapy or radiotherapy. During the 6-month study period, seven patients experienced symptomatic recurrent VTE (cumulative incidence, 5.9%), and two patients experienced incidental recurrent PE (cumulative incidence of any recurrent VTE, 7.6%). Major bleeding events occurred in six patients (cumulative incidence, 5.3%) and CRNM bleeding events in 11 patients (cumulative incidence, 10.2%). Twenty-eight patients (overall mortality, 24.0%) died. CONCLUSIONS Rivaroxaban is effective and safe for the treatment of VTE in patients with active cancer.